The present invention provides an isolated human or human-adapted antibody antagonist or fragment thereof that specifically binds Domain I (SEQ ID NO: 9) of human interleukin-1 receptor like 1 (ST2L), comprising a heavy chain complementarity determining region (HCDR) 1 (HCDR1), a HCDR 2 (HCDR2), a HCDR 3 (HCDR3), a light chain complementarity determining region (LCDR) 1 (LCDR1), a LCDR 2 (LCDR2), and a LCDR 3 (LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR1, and LCDR3 comprise: a) SEQ ID NOs: 95, 109, 84, 130, 90 and 131, respectively； b) SEQ ID NOs: 97, 111, 84, 130, 90 and 131, respectively； c) SEQ ID NOs: 96, 110, 84, 130, 90 and 134, respectively； d) SEQ ID NOs: 97, 111, 84, 130, 90 and 134, respectively； e) SEQ ID NOs: 97, 112, 84, 130, 90 and 134, respectively； f) SEQ ID NOs: 98, 113, 84, 130, 90 and 134, respectively； g) SEQ ID NOs: 97, 115, 84, 130, 90 and 134, respectively； h) SEQ ID NOs: 99, 116, 84, 130, 90 and 133, respectively； i) SEQ ID NOs: 100, 117, 84, 130, 90 and 133, respectively； j) SEQ ID NOs: 101, 118, 84, 130, 90 and 133, respectively； k) SEQ ID NOs: 102, 120, 84, 130, 90 and 132, respectively； l) SEQ ID NOs: 103, 121, 84, 130, 90 and 132, respectively； m) SEQ ID NOs: 103, 122, 84, 130, 90 and 131, respectively； n) SEQ ID NOs: 103, 123, 84, 130, 90 and 131, respectively； o) SEQ ID NOs: 104, 124, 84, 130, 90 and 131, respectively； p) SEQ ID NOs: 105, 125, 84, 130, 90 and 131, respectively； q) SEQ ID NOs: 106, 126, 84, 130, 90 and 131, respectively； r) SEQ ID NOs: 95, 127, 84, 130, 90 and 131, respectively； s) SEQ ID NOs: 107, 128, 84, 130, 90 and 131, respectively； t) SEQ ID NOs: 108, 129, 84, 130, 90 and 131, respectively； u) SEQ ID NOs: 24, 28, 146, 36, 40 and 147, respectively； or v) SEQ ID NOs: 24, 28, 146, 36, 40 and 44, respectively.
